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Abstract
Background: Rheumatoid arthritis (RA) and cigarette smoking are both risk factors for periodontal disease (PD).
Previous research suggests that systemic inflammatory conditions and cigarette smoking may act in synergy, and
their co-occurrence leads to a much higher risk of developing severe stage PD than what the combination of
their individual risks would suggest. We originally sought to test this in the case of RA, but it turned out that the majority
of our patients were former smokers, who smoked for prolonged periods in the past. For that reason, we decided to shift
our focus toward the possible effects of past chronic cigarette smoke exposure.
Methods: The data of 73 RA patients and 77 healthy controls were analyzed. The participants received a full-mouth
periodontal examination to determine their periodontal status. Rheumatological indices and data on past tobacco use
were also recorded. Both the patient and the control groups were divided into former smoker and non-smoker
subgroups for the analyses. Non-smoker controls were used as the reference group.
Results: In the control group, smoking in history increased the odds of developing both the moderate and the severe
stages of PD, but the change was not statistically significant. RA significantly, increased the odds of developing both
stages in itself, but the highest odds were seen in the former smoker RA group.
Conclusion: Based on this surprising observation of ours, we hypothesize that chronic cigarette smoke might bring
about permanent changes in the periodontal tissues, leading to their hypersensitivity to inflammatory challenges.
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Background
The connection between periodontal disease (PD) and
various systemic conditions of an autoimmune/dysim-
mune background is well documented [1–5]. Rheumatoid
arthritis (RA) is an immune mediated disease with a par-
ticularly well established link to PD [6–9]. While the exact
immunological mechanisms have not been clarified, there
is evidence to suggest that the presence of citrullinated
proteins (and antibodies against them) is the link [10–12].
In this respect, the role of the periodontal pathogen, Por-
phyromonas gingivalis is emphasized, the only periodontal
pathogen that expresses the citrullinating enzyme
peptidyl-arginine deiminase (PPAD) [9, 13, 14]. Compared
to the general population, subjects with PD are at an
increased risk of developing RA, and vice versa [9, 15],
which suggests that once they are established, they mutu-
ally aggravate each other.
Cigarette smoking is a known risk factor for both PD
[16–18] and RA [19–21]. Cigarette smoking promotes
oral bacterial colonization [22] and smoking itself has
been shown to promote citrullination [23], evidenced by
the fact that an association was found between tobacco
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exposure and anti-cyclic citrullinated peptide (anti-
CCP) titers in RA patients [24]. It follows that
cigarette smoking may be an additional aggravating
factor in both PD and RA, especially when the two
conditions are comorbid.
In 2014, we published a study about the effects of
cigarette smoking on the severity of PD in psoriasis [25].
In that study, we found that while both psoriasis and
smoking significantly elevated the odds that the individ-
ual will develop advanced PD, when both risk factors
were present, the odds multiplied, well beyond the com-
bined odds. We concluded that cigarette smoking prob-
ably acted as a permissive factor, and we articulated a
hypothesis about the possible role of toll-like receptor 4
(TLR-4). The hypothesis was that smoking exerts this ef-
fect through the upregulation of TLR-4.
In their review [26], Baka and co-workers point out
that as cigarette smoking promotes bacterial colonization,
it may well be that smokers are exposed to an increased
burden of P. gingivalis, whereby they are constantly ex-
posed to a potent antigen.
Based on these premises, we wished to find out about
if smoking acts as a booster of periodontal deterioration
also in the context of RA. This is an important question
with practical bearings. For instance, severe PD was
reported to hamper the efficacy of anti-TNF (tumor ne-
crosis factor) therapy [27].
To answer the question, we collected data on 82 RA
patients and 100 controls who met all the inclusion and
exclusion criteria and also gave their informed consent.
At this point, though, we were faced with a difficulty:
most of our patients turned out to be non-smokers
(NS). Only eight of them smoked at the time of the
study, and the rest had either quit or never ever smoked
in their lives. The majority of our patient sample, there-
fore, consisted of non-smokers and former smokers (FS)
who had quit smoking long before.
While we have a wealth of information about the im-
munological consequences of current smoking [28–31],
we know almost nothing about the permanent immuno-
logical changes that chronic exposure to cigarette smoke
may bring about - and that may remain even if the smoker
quits. Considering that the majority of our formerly smok-
ing patients had smoked for at least a decade before they
quit, and that chronic exposure to cigarette smoke was
proven to induce genome level changes [32–34], we
decided to shift our focus and concentrate on the effects
of past smoking. We hypothesized that the periodontal
status of patients with no smoking history would be sig-
nificantly poorer than that of healthy controls (the effect
of RA), and we wished to know if past smoking would be
associated with poorer periodontal status to any extent.
We were also interested in the relationship between the
rheumatological factors and the periodontal status.
Methods
Both RA patients and healthy controls were recruited on
a voluntary basis.
Patients were eligible for the study if they met the
2010 European League against Rheumatism and
American College of Rheumatology (EULAR/ACR)
criteria for rheumatoid arthritis [35]. Exclusion
criteria for both groups were determined based on
the literature of the subject and included obesity
(body mass index - BMI≥30), excessive alcohol con-
sumption, drug abuse, diabetes mellitus, diseases causing
neutropenia and local or systemic inflammatory condi-
tions (other than RA) [36]. Poor oral hygiene, defined as
Simplified Oral Health Index (OHI-S)- > 3 [37] was also
an exclusion criterion.
Required sample size was calculated with G*Power 3.1.
5. (University of Kiel, Germany), a software designed
especially for statistical power and sample size computa-
tion [38]. The software allows the computation of
achieved statistical power (post-hoc) and required sam-
ple size (a priori). As mostly categorical variables were
to be analyzed, a priori sample size estimation was per-
formed for crosstabs/chi square/contingency tables, with
the following input parameters: effect size (w): 0.3; α: 0.
05;power (1-β): 0.9; df: 3. Required sample size turned
out to be n = 158 (for four groups: RA smoker/former
smoker; control smoker/former smoker).
RA Patients (n = 82) were recruited from among the
patients of the Department of Rheumatology, University
of Szeged. The control group (n = 100) was recruited
from among people attending mandatory lung screening
in the same city and the same period. After removing
the actual smokers from the sample, we were left with
150 participants (73 patients and 77 controls), yielding a
statistical power of 0.88.
The study was approved by the Institutional and Re-
gional Ethics Committee for Medical Biological Research
at the University of Szeged (approval No.144/2014), and
the study design conformed to the Declaration of
Helsinki in all respects. Written informed consent was
obtained from all participants.
Demographic and tobacco use data were collected by a
questionnaire. Participants were divided into FS and
non-smoker groups, based on their self-reported tobacco
use in the past. In both the patient and the control
groups, a subject was considered a FS if they smoked for
at least one year in the past as a habit and without inter-
ruption. Sixty-four percent of the FS controls and 74 %
of the FS RA patients provided tobacco use information
that could be used for the analyses.
The clinical disease severity of PD is still a matter of
debate, and several methods are available in the litera-
ture [39]. We decided to use the staging proposed by
Fernandes and colleagues [40]. The reason for using this
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classification was that its clinical staging matches the
pathological/pathophysiological changes in PD very well
[41], and that we had had previous experience with it
[25]. The staging requires the following parameters to be
recorded: bleeding on probing (BOP; the presence or ab-
sence of bleeding within 15 s after probing), probing
depth (PRD; in millimeters), and clinical attachment
level (CAL; to describe the position of the soft tissue in
relation to the cemento-enamel junction). All subjects
received a full-mouth examination and their periodontal
status was classified into one of the four categories of
the staging: healthy(0); early (1); moderate (2); severe (3).
For the examination, Williams probes (Hu-Friedy Manu-
facturing Co., Chicago, USA) were used. Table 1 shows
the categories of the applied staging and the correspond-
ing pathological/pathophysiological status. Although
there is some lack of overlap in the first stage of the PD,
it may not influence any of the results as nor the initial
lesion, nor the gingivitis is having real influence on the
immune sytem and the gingival health. Gingivitis itself is
a reversible form of the disease.
To characterize the patient population from a
rheumatological point of view, the following indices
and laboratory values were recorded: IgM rheumatoid
factor seropositivity and levels (RF) measured with
nephelometry, anti-citrullinated peptide antibody
(ACPA) seropositivity and levels with antigenic speci-
ficity to mutated citrullinated vimentin (aMCV) mea-
sured with ELISA, disease activity score (DAS28-ESR)
at the latest visit and its average of the past
12 months, and the HAQ-DI disability index. Data on
the conventional and biological disease modifying anti-
rheumatic drug (DMARD) and corticosteroid therapy of
the patients were also recorded. Laboratory values were
determined as part of the routine examinations (i.e. not
especially for this study).
We divided the subjects into four groups based on the
presence/absence of RA and smoking in the past. To ex-
press the odds that a member of a given group develops
a given clinical degree of periodontal disease, multi-
nomial logistic regression analysis was conducted and
the odds ratios were calculated. In the multinomial
Table 1 The applied clinical staging and the corresponding pathological/pathophysiological changes [40, 41]
CLINICAL STAGING (Fernandes et al., 2009) PATHOLOGY/PATHOPHYSIOLOGY (Ohlrich et al., 2009)
1.NO CLINICAL SIGNS- no clinical attachment loss
(CAL) or bleeding on probing (BOP)
(NO LESION- NOT CLASSIFIED EXPLICITLY IN OHLRICH ET AL.)
(GINGIVITIS-NOT CLASSIFIED EXPLICITLY IN
FERNANDES ET AL.)
1. INITIAL LESION – up to 4 days following plaque accumulation. Polymorphonuclear
leukocytes (PMN), complement activation, loss of connective tissue. Mast cells release tumor
necrosis factor alpha, PMNs migrate into the gingival sulcus, but as the bacteria are protected
by the biofilm, abortive phagocytosis occurs. PMNs release lysosomal contents, which leads
to further tissue destruction.
2.EARLY PERIODONTITIS- CAL
≥1 mm in ≥2 teeth
2. EARLY/STABLE LESION- 7-21 days after plaque accumulation, clinically evident approxi-
mately from day 12. Dominantly macrophages and lymphocytes (CD4+:CD8+ 2:1).
Perivascular inflammatory infiltrate. Intercellular spaces between epithelial cells widen,
bacterial products infiltrate the gingival tissues at a higher rate. Escalation of response.
If plaque removed, tissue remodeling can take place.
3.MODERATE PERIODONTITIS- 3 sites with CAL
≥4 mm and at least 2 sites with
probing depth (PRD) ≥3 mm
3. ESTABLISHED OR PROGRESSIVE LESION- dominantly a B cell/plasma cell response. High
levels of IL-1 and IL-6: connective tissue loss, breakdown of bone.
4. SEVERE PERIODONTITIS- CAL ≥6 mm in ≥2 teeth
and PRD ≥5 mm in ≥1 site
4. ADVANCED LESION- Overt loss of attachment. High levels of IL-1, TNF α and PGE2 stimulate
fibroblasts and macrophages to produce matrix metalloproteases. The junctional epithelium
progresses in apical direction (deepening periodontal pocket).
Oligoclonal Th2 (CD4
+) dominance.
Table 2 Demographic and tobacco use characteristics of the studied groups








CNS (n = 55) 44(80):11(20) NA NA NA 55.7 (13.3)
CS (n = 22) 12(54):10 (45) 11.3(12.5) 13.8(10.2) 11 (7.9) 58.1 (13.5)
PNS (n = 42) 33(79): 9 (21) NA NA NA 56.5 (12.7)
PS (n = 31) 24(77):7 (23) 16.4(12.2) 18.3(11.4) 14 (10.2) 59.3 (13.6)
CNS control, never smoked, CS control, used to smoke, PNS patient, never smoked, PS patient, used to smoke
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model, disease severity (healthy, early, moderate, severe)
was defined as the outcome variable, group was the
factor, and age and sex were covariates. Within-group
analyses (Mann-Whitney U tests) were also performed
in the patient group, according to the smoking status,
to see if past smoking had any effect on the rheum-
atological indices. For the analyses, SPSS 21.0 (IBM,
USA) was used.
Results
The demographic and tobacco use characteristics of the
four studied groups are given in Table 2. It can be seen
that the vast majority of the participants were females.
This is because RA affects predominantly women and
the control group was selected to match the patient
group age- and gender-wise as closely as possible.
The within-group comparisons in the patient group
did not indicate significant difference in any of the
rheumatological indices between FS and non-smokers
(data not shown). To test the effect of RF/aMCV positiv-
ity on periodontal status, a separate multinomial regres-
sion analysis was conducted. While no statistically
significant effects were found, seropositivity for RF
increased the odds of the moderate stage to 1.65, and
that of the severe stage to 2.51. The rheumatological in-
dices of the patient group are summarized in Table 3.
The periodontal status and CAL data of each group is
shown in Table 4. It is noteworthy that while the major-
ity of the cases in both control groups falls into the
healthy and early stages, in the patient groups the situ-
ation is just the opposite. This tendency is the most re-
markable among the patients who used to smoke. 81%
of them were classified as having moderate or severe
PD. Note also that in the patient groups nobody was
found who could be classified as periodontally healthy.
The results of the multinomial regression analysis are
given in Table 5. The analysis indicated no significant in-
fluence of either age or sex on periodontal status. Male
Table 3 A brief rheumatological characterization of the patient population by smoking in patient history
Rheumatoid factor positivity [> 30 U/ml] n (%) FS 20 (64.5)
NS 24 (57.1)
Anti-citrullinated peptide antibody positivity [> 20 U/ml] n(%) FS 20 (64.5)
NS 25 (59.5)
Patients on conventional DMARD therapy n (%) FS 25 (80.6)
NS 36 (85.7)
Patients on biological DMARD therapy (%) FS 17 (54.8)
NS 18 (42.8)
DAS28 at visit mean (SD; range) FS (n = 21) 3.10 (1.42; 0.97–6.52)
NS (n = 35) 2.94 (1.30; 0.79–6.33)
Average DAS28 in the previous 12 months mean (SD; range) FS (n = 10) 3.20 (1.68; 1.38–5.22)
NS (n = 8) 2.41 (1.30; 1.20–5.30)
HAQ mean (SD) FS (n = 15) 0.98 (0.84)
NS (n = 7) 2.21 (0.70)
FS former smoker, NS never smoked, DMARD disease-modifying antirheumatic drug, DAS28 disease activity score, HAQ score on the health assessment questionnaire for
rheumatoid arthritis. Where data from not all patients were available, the actual number of patients is given in parentheses
Table 4 Periodontal status in the examined groups according to Fernandes et al. (38). Data are given as n (%, rounded percentages).
CAL values are also shown (mm, mean ± SD). The conventions are the same as in Table 1
RA Control
n CAL n CAL
Total 73 3.55 (±1.62) 77 2.03 (±1.17)
PNS PS CNS CS
n CAL n CAL n CAL n CAL
Total 42 3.18 (±1.39) 31 4.06 (±1.79) 55 2.08 (±1.26) 22 1.91 (±0.89)
Healthy 0 NA 0 NA 8 (15) 0.67 (±0.30) 4 (18) 0.76 (±0.40)
Early 12 (29) 1.81 (±0.21) 6 (19) 1.89 (±0.31) 30 (55) 1.52 (±0.39) 12 (55) 1.76 (±0.37)
Modrate 22 (52) 3.07 (±0.32) 12 (39) 3.50 (±0.89) 13 (24) 3.35 (±0.21) 5 (23) 3.19 (±0.25)
Severe 8 (19) 5.52 (±1.21) 13 (42) 5.57 (±1.46) 4 (7) 4.99 (±0.14) 1 (5) 4.72 (±NA)
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sex appears to be associated with an increased risk for
both the moderate and the severe stages, but given the
under-representation of the male sex in this study, we
would not draw conclusions from this. As for the odds
of developing the moderate or severe stages, these were
significantly higher in both patient groups for both
stages as compared to controls who never smoked. Con-
trols who used to smoke did not have significantly
higher odds to develop any of these stages than controls
who never smoked, while an increment was definitely
seen. The highest significant odds ratio for the severe
stage (16.25) was found in the RA group of FS.
Discussion
A part of these findings is merely the corroboration of
known facts. RA has been known as a risk factor for PD
for some time [6–8], and our results demonstrate the
same: the presence of RA in itself is enough to signifi-
cantly increase the odds that the patient will develop a
more severe stage of PD.
We also found that past smoking did not have a sig-
nificant effect on any of the rheumatological indices and
that there was no association between these indices and
periodontal status. The lack of the effect of past smoking
on the rheumatological status as expressed by these indi-
ces might be best explained by the time passed since the
patient stopped smoking. While cigarette smoke must
have been an extra immunological stimulus while the
patient was still smoking, and it might as well have
boosted the immunological memory against citrullinated
proteins [42], these effects are unlikely to be reflected in
indices characterizing a much narrower time window.
How come that no association was found between the
specific RA indices and the periodontal status, while, as
pointed out before, being in the RA group in itself sig-
nificantly increased the odds of the more severe PD
stages? Given that other studies describing larger popu-
lations found significant association with rheumatoid
factor positivity and anti-citrullinated peptide antibody
production [43, 44], we think that our sample size
was probably too small to allow reliable assessment at
the level of the individual indices, considering their
greater variability.
The main finding of this study, however, is also the
most difficult to explain. The finding that the FS RA
patients had the highest and significant odds ratio for
the severe stage of PD is really an unexpected one. From
the results it appears that the effect is not mediated by
the actual rheumatological status, the presence of RA
with a longer period of cigarette smoke exposure in the
past is enough. This suggests that long-term cigarette
smoking might permanently sensitize the periodontium,
but at this point we could only speculate about the pos-
sible mechanisms, and it is because of that reason that
we put this up for debate.
Conclusions
While this study definitely has its limitations, we think
that our quasi-accidental finding about the effect of past
smoking on periodontal health in RA deserves attention.
This finding implies that long-term exposure to cigarette
smoke might have a permanent sensitizing effect on the
human periodontal tissues, which is not reversible by
quitting smoking.
Abbrevations
ACP: Anti-citrullinated peptide antibody; aMCV: Mutated citrullinated
vimentin; anti-CCP: Anti-cyclic citrullinated peptide; anti-TNF: Anti-tumor
necrosis factor; BMI: Body mass index; BOP: Bleeding on probing;
Table 5 Results of the multinomial regression analysis. The odds ratios (Exp(B)) express the odds that a member of the given group
develops the given stage of periodontal disease. Controls who never smoked and early stage periodontal disease served as reference
(as no periodontally healthy individuals were found in the patient group, healthy could not be used as reference). B: correlation
coefficient; df: degrees of freedom
Periodontal status (reference: early) B df Sig. Exp(B) 95% CI for Exp(B)
moderate RA- used to smoke 1.529 1 0.011 4.615 1.423–14.966
RA- never smoked 1.442 1 0.003 4.231 1.623–11.030
Control- used to smoke 0.932 1 0.090 2.538 0.866–7.442
Control-never smoked – – – – –
Male sex 0.223 1 0.643 1.250 0.487–3.212
Age 0.002 1 0.896 1.002
severe RA- used to smoke 2.788 1 0.000 16.250 3.917–67.412
RA- never smoked 1.609 1 0.022 5.000 1.265–19.762
Control- used to smoke 0.405 1 0.666 1.500 0.238–9.465
Control-never smoked – – – – –
Male sex 0.839 1 0.867 2.315 0.703–7.619
Age 0.028 1 0.176 1.029 0.972–1.033
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CAL: Clinical attachment level; CNS: Control, never smoked; CS: Control, used
to smoke; DAS28-ESR: Disease activity score; FS: Former smokers; NS: Non-
smokers; OHI-S: Simplified Oral Health Index; PD: Periodontal disease;
PNS: Patient, never smoked; PPAD: Peptidyl-arginine deiminase; PRD: Probing
depth; PS: Patient, used to smoke; RA: Rheumatoid arthritis; RF: Rheumatoid
factor; TLR-4: Toll-like receptor 4
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